"On Tuesday, the company announced positive interim data on TTI 621. Soon enough the trading volumes on the stock rose significantly. “The program continues to demonstrate clear single agent activity across a range of hematologic malignancies, as well as a strong tolerability profile. We believe that TTI-621, even at these low initial doses, is the only anti-CD47 agent that has shown meaningful single agent activity, including complete responses,” said Dr. Jan Skvarka, President and Chief Executive Officer of Trillium."
SOURCE: 5 Penny Stocks To Watch Before Next Week; 1 Up 720 % Since December
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
